文献速递肿瘤 PET/CT骨显像与常规 SPECT

泼尼松龙及短期停用泼尼松龙对风湿性多肌痛FDG-PET/CT诊断准确性的影响——101例患者的前瞻性研究

The effect of prednisolone and a short-term prednisolone discontinuation for the diagnostic accuracy of FDG-PET/CT in polymyalgia rheumatica-a prospective study of 101 patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-04-02

该前瞻性研究纳入101例疑似风湿性多肌痛(PMR)初治患者,在基线、泼尼松龙治疗8周后及短期停药后分别行FDG-PET/CT,以1年临床随访为最终诊断。基线FDG-PET/CT的敏感性/特异性为86%/63%(Leuven评分)和82%/70%(二分类评分);治疗8周后敏感性降至36%/41%,短期停药后回升至66%/60%。结论认为FDG-PET/CT鉴别PMR与其他炎症性疾病的能力有限,若用于诊断目的应停用泼尼松龙以提高诊断准确性。

要点

  • 基线FDG-PET/CT诊断PMR的敏感性/特异性:Leuven评分86%/63%,二分类评分82%/70%。
  • 泼尼松龙治疗8周后敏感性降至36%/41%(Leuven/二分类评分)。
  • 短期停用泼尼松龙后敏感性回升至66%/60%(Leuven/二分类评分)。

核心结论

  • FDG-PET/CT鉴别PMR与其他炎症性疾病的诊断准确性有限。
  • 若FDG-PET/CT用于诊断目的,应停用泼尼松龙以提高诊断准确性。

研究设计与样本

  • 前瞻性研究,纳入101例初治疑似PMR患者,基线临床诊断后行FDG-PET/CT。
  • 确诊PMR者予泼尼松龙,治疗8周后行第二次FDG-PET/CT,第9周短期停药,第10周行第三次FDG-PET/CT。
  • 采用经验证的Leuven评分与二分类PMR评分进行分类,最终诊断基于1年临床随访。
  • 试验注册号ClinicalTrials.gov NCT04519580,注册日期2020年8月17日。

主要发现

  • 最终临床诊断为PMR者68例,非PMR者27例。
  • 基线FDG-PET/CT诊断PMR的敏感性/特异性:Leuven评分86%/63%,二分类评分82%/70%。
  • 非PMR炎症性疾病亚组与PMR组比较,特异性为39%/54%(Leuven/二分类评分)。
  • 泼尼松龙治疗8周后敏感性降至36%/41%(Leuven/二分类评分)。
  • 短期停用泼尼松龙后敏感性升至66%/60%(Leuven/二分类评分)。

关键数值与推荐

  • 基线FDG-PET/CT敏感性/特异性:Leuven评分86%/63%,二分类评分82%/70%。
  • 非PMR炎症性疾病亚组对比PMR组特异性:Leuven评分39%,二分类评分54%。
  • 治疗8周后敏感性:Leuven评分36%,二分类评分41%。
  • 短期停药后敏感性:Leuven评分66%,二分类评分60%。

临床怎么用

  • 作者认为FDG-PET/CT鉴别PMR与其他炎症性疾病的诊断准确性有限。
  • 作者建议若FDG-PET/CT用于诊断目的,应停用泼尼松龙以提高诊断准确性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 2-[18F]Fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) has been suggested as an imaging modality to diagnose polymyalgia rheumatica (PMR). However, the applicability of FDG-PET/CT remains unclear, especially following glucocorticoid administration. This study aimed to investigate the diagnostic accuracy of FDG-PET/CT before and during prednisolone treatment, as well as following short-term prednisolone discontinuation. METHODS: Treatment naïve suspected PMR patients were clinically diagnosed at baseline and subsequently had an FDG-PET/CT performed. Patients diagnosed with PMR were administered prednisolone following the first FDG-PET/CT and had a second FDG-PET/CT performed after 8 weeks of treatment. Subsequently, prednisolone was tapered with short-term discontinuation at week 9 followed by a third FDG-PET/CT at week 10. An FDG-PET/CT classification of PMR/non-PMR was applied, utilizing both the validated Leuven score and a dichotomous PMR score. The final diagnosis was based on clinical follow-up after 1 year. RESULTS: A total of 68 and 27 patients received a final clinical diagnosis of PMR or non-PMR. A baseline FDG-PET/CT classified the patients as having PMR with a sensitivity/specificity of 86%/63% (Leuven score) and 82%/70% (dichotomous score). Comparing the subgroup of non-PMR with inflammatory diseases to the PMR group demonstrated a specificity of 39%/54% (Leuven/dichotomous score). After 8 weeks of prednisolone treatment, the sensitivity of FDG-PET/CT decreased to 36%/41% (Leuven/dichotomous score), while a short-term prednisolone discontinuation increased the sensitivity to 66%/60%. CONCLUSION: FDG-PET/CT has limited diagnostic accuracy for differentiating PMR from other inflammatory diseases. If FDG-PET/CT is intended for diagnostic purposes, prednisolone should be discontinued to enhance diagnostic accuracy. TRIAL REGISTRATION: ClinicalTrials.gov (NCT04519580). Registered 17th of August 2020.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Nielsen AW, Hansen IT, Nielsen BD, et al. The effect of prednisolone and a short-term prednisolone discontinuation for the diagnostic accuracy of FDG-PET/CT in polymyalgia rheumatica-a prospective study of 101 patients. Eur J Nucl Med Mol Imaging. 2024. PMID: 38563881. doi:10.1007/s00259-024-06697-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。